Eyenovia, Inc. (EYEN) analyst actions
Rating and price-target actions on EYEN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the EYEN overview →
1 measured EYEN analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States | Press release | -3.09% | -3.10% |
Keep exploring
More EYEN: earnings → · SEC filings → · EYEN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | 267 | 0.00% | 44% |
| Galapagos NV - American Depositary Shares (GLPG) | 267 | -0.05% | 44% |
| Qiagen N.V. Common Shares (QGEN) | 266 | +0.05% | 53% |
| 22nd Century Group, Inc (XXII) | 266 | -1.87% | 30% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.